A Longitudinal Observational Cohort Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
Phase of Trial: Phase IV
Latest Information Update: 16 Feb 2017
At a glance
- Drugs NSI 189 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Neuralstem
- 16 Feb 2017 According to a Neuralstem media release, results will be available in the first half of 2018.
- 12 Aug 2016 Status changed from not yet recruiting to recruiting.
- 05 Apr 2016 New trial record